Ray Therapeutics, Inc.’s Post

Luka Jelcic recently released an updated R&D pipeline overview of AI-first biotech players! Luka's updated overview highlights a net addition of ~50 new programs, with oncology remaining strong and increased activity in neurology and endocrine/metabolic spaces, while autoimmune and cardiovascular programs have slightly decreased. Women's health and dermatology are growing robustly, and several players are developing new diagnostic and disease characterization platforms. For more detailed insights and to stay updated, check out his full LinkedIn post: https://lnkd.in/gASEH2gy Connect with Luka to explore how DeciBio can support your AI-first biotech initiatives and drive innovation together. #Biotech #AI #Innovation *Graphic shows all players who have an active program in a specific stage and therapeutic area.

𝐅𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐄𝐧𝐝𝐨𝐬𝐜𝐨𝐩𝐢𝐜 𝐒𝐢𝐧𝐮𝐬 𝐒𝐮𝐫𝐠𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $1.7 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2029 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞:-https://lnkd.in/dnTQpQdY The size of global functional endoscopic sinus surgery market in terms of revenue was estimated to be worth $1.2 billion in 2024 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 7.6% from 2024 to 2029. Functional endoscopic sinus surgery Dynamics ✅ DRIVER: High prevalence of chronic sinusitis ✅RESTRAINT: Availability of non-surgical treatment ✅OPPORTUNITY: Growing demand for organ transplants and cell & gene therapy ✅CHALLENGE: Storage and transportation logistics Based on the region, the Functional endoscopic sinus surgery market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC. The North America market is driven by availability of technologically advanced products and growing acceptance for MIS. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Medtronic Stryker Olympus Corporation  BKK B. Braun Melsungen AG KARL STORZ #SinusSurgery #ENTInnovation #FESS #MinimallyInvasiveSurgery #MedicalDevices

HEALTH, MEDICAL & BIOTECH: ORTHOPEDIC & MUSCULOSKELETAL SOLUTIONS — ELEVIDYS (delandistrogene moxeparvovec-rokl) by Sarepta Therapeutics: ELEVIDYS is the first FDA-approved gene therapy for Duchenne and the first gene therapy to address the root cause of the muscle-wasting disease. Sarepta developed a way to replace the broken dystrophin gene with a working version that protects muscles, thereby slowing disease progression. It offers hope to those living with the fatal disease. — SurgicalAR® by Medivis: Medivis leverages AR, AI and computer vision to bring accuracy and precision to surgeries. Our SurgicalAR technology translates complex 2D medical imaging such as MRIs and CTs into 3D holographic visualizations to enhance surgical accuracy and patient outcomes, reducing operational risks, and ultimately, elevating the standard of care globally. — SutureLoc™ Implant by Arthrex, Inc.: SutureLoc is the first knotless, retensionable soft anchor designed specifically for arthroscopic meniscal root repair. The all-suture soft anchor is designed for retrograde insertion directly under the repair subcortically, improving fixation strength and stiffness by eliminating suture fixation devices in the anterior tibia. — #EdisonAwards2024 #2024EdisonAwardsFinalist #health #medical #biotech 

Stealth BioTherapeutics presented new #bevemipretide (SBT-272) preclinical data from a study demonstrating topical #ocular delivery to the #retina with protective effects observed in models of age-related macular degeneration (#AMD). The aim of the study was to evaluate ocular and systemic distribution of #topical bevemipretide and its potential protective effects in models of AMD. The study looked at bevemipretide, which targets the inner #mitochondrial membrane where it reversibly binds to cardiolipin. This improves mitochondrial function and reduces the production of reactive oxygen species (ROS). This article was published in Ophthalmology Times. https://lnkd.in/g3bUHdKc Pic (c) Wikipedia

Hear more about Neurotech Pharmaceuticals, Inc.'s Encapsulated Cell Therapy Platform for the treatment of Macular Telangiectasia (MacTel) from Neurotech's CEO, Rich Small. MacTel is a bilateral retinal disease that leads to a gradual loss of central vision. The disease causes photoreceptors to be lost in a well-defined area (Ellipsoid Zone) of the retina. As the disease progresses, patients experience blurring, distorted vision, trouble reading, and loss of central vision. #mactel #retina #raredisease #neurotech #OTF2024 #ophthalmicinnovation

🚀Exciting developments from EHA 2024! Dr Hanne Norseth from the Oslo Myeloma Center presented the results of the phase I/II TG01 study. This study explores the safety and efficacy of the TG01/QS-21 vaccine in patients with KRAS or NRAS mutations. While the vaccine was well-tolerated, further evaluation is needed to determine its clinical efficacy. Stay tuned for more updates on this innovative approach in multiple myeloma treatment. For all EHA 2024 videos, find the link in the comments! 👇 #MediMix #Hematology #MultipleMyeloma #Innovation

🚀 Revolutionizing Vitiligo Management with miRNA Technology! 🚀 In recognition of #WorldVitiligoDay this past Tuesday, June 25th, we are excited to spotlight a groundbreaking innovation from IMIBIC researchers addressing the pressing needs of non-segmental vitiligo patients. 🔬 What is Non-Segmental Vitiligo? Non-segmental vitiligo is an immune-mediated inflammatory disease causing the apoptosis of melanocytes, leading to the loss of skin pigmentation. This condition affects approximately 0.5-2% of the population, translating to around 900,000 individuals only in Spain. 💡 Innovation Researchers have developed a pioneering kit based on RT-PCR analysis of human miRNAs from skin or peripheral blood samples. This kit enables: 🔹 Classification of Patients: Assess the severity and prognosis of non-segmental vitiligo. 🔹 Therapeutic Monitoring: Track response to various systemic treatments, both in development and approved. 🔹 Predictive Analysis: Serve as a molecular predictor for therapeutic response. 🌟 Why This Matters: Current clinical practices lack specifically targeted, effective treatments for non-segmental vitiligo. This technology leverages the identification of 90 miRNAs with altered expression in affected tissues and plasma, providing a reliable marker for disease progression and therapeutic response. This innovation promises to enhance patient care through objective, reproducible measures compared to traditional image-based scales. 📈 Advantages: - Objective and reproducible - Early detection of therapeutic response - Potential to significantly improve quality of life for patients 🔄 Current Status: The miRNAs are currently being validated in a broader population to finalize the prototype kit. If you want to know more or explore collaboration opportunities, do not hesitate to contact me. #TechTrans4ndalucia #OTTSSPA #TechsMadeinAndalucia #HealthcareInnovation #Vitiligo #WorldVitiligoDay #miRNA #PersonalizedMedicine #Biotechnology #FIBICO #Healthcare #RT-PCR #Dermatology #MedicalResearch Fundación Progreso y Salud

𝗕𝗲𝘁𝘁𝗲𝗿 𝗗𝗮𝘁𝗮 𝗳𝗼𝗿 𝗕𝗲𝘁𝘁𝗲𝗿 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 📊 Our innovative OFM (Open Flow Microperfusion) sampling technology is a valuable tool for PK-PD studies in neuroscience 🧠, dermatology👨⚕️, oncology 🧬 and biomarker research 🔬. Minimally invasive, membrane-free OFM probes enable access to the entire biochemical information of the interstitial fluid from brain and peripheral tissues, opening new horizons in preclinical and clinical drug testing🌟. 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁💡 OFM studies reduce costs by providing a complete pharmacological profile early in drug development. 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱🎯 OFM probes enable continuous sampling from clearly specified tissue types. 𝗨𝗻𝗶𝘃𝗲𝗿𝘀𝗮𝗹 🌐 OFM samples all substances from the interstitial fluid, independent of size, lipophilicity, or protein-binding. #JRHealth #OpenFlowMicroperfusion #OFM #ClinicalResearch #PreClinicalResearch #InnovationInMedicine

These results are confirming the strength of our technology.  Novadip is the only company to develop new biological products in the orthopedic field to demonstrate the full safety But mainly to demonstrate a superiority of the efficacy for challenging clinical situations associated to a poorer bone healing outcomes (aging population, diabetes, obesity, smoking and medication use,...) We want to become a game changer

As a resident in ophthalmology, every day is a mix of excitement, learning, and commitment. The balance between clinical duties, surgeries, and staying updated on the latest research can be intense, but it’s driven by a passion for restoring sight and improving lives. One of the biggest challenges in ophthalmology is the delicate balance between precision and speed. Whether diagnosing complex retinal diseases or performing microsurgery, each step requires full focus and mastery. But that's what makes this field so rewarding—knowing that even the smallest interventions can have life-changing effects. Looking ahead, the future of ophthalmology is incredibly promising. From AI-powered diagnostics to advancements in gene therapy and minimally invasive procedures, the potential to revolutionize patient care is immense. It’s exciting to be at the forefront of a field that's constantly evolving! Here’s to all my colleagues and future ophthalmologists—let’s continue pushing boundaries and making a difference! 🙌 #Ophthalmology #ResidentLife #MedicalInnovation #FutureOfHealthcare #SurgicalPrecision